Lucid Diagnostics (NASDAQ:LUCD) reported positive data from a study showing that its EsoGuard esophageal DNA test can detect ...

Lucid Diagnostics shared new data from a National Cancer Institute (NCI)-sponsored study that supports the broader utility of its EsoGuard(R) Esophageal DNA Test. The study, condu ...

Lucid Diagnostics (LUCD) announced positive data from a National Cancer Institute-sponsored study demonstrating that its EsoGuard Esophageal ...

These results support EsoGuard esophageal precancer testing in an expanded target population, consistent with existing American Gastroenterological Association (AGA) guidelines and has the ...

A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval.

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy The ENVET-BE study reviewed real-world data from a ...

Lucid believes EsoGuard, performed on samples collected non-endoscopically with EsoCheck, is the missing element – the first and only commercially available test capable of serving as a ...

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing For more information about Lucid, please visit www.luciddx.com and for more information about ...